Fennec Pharmaceuticals Inc. (NasdaqCM: FENC)
Health Care · Biotechnology · US
$11.58
+2.57% today · +30.4% 1Y
Fennec Pharmaceuticals Inc. (NasdaqCM: FENC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $395.91M and employs 35 people.
Over the last twelve months the share price has gained 30.4%, trading between 5.65 and 13.25.
Tweenvest scores Fennec Pharmaceuticals Inc. across four factors: quality 49/100, value 60/100. Its strongest factor is value.
FENC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $395.91M
- Revenue (TTM)
- $59.22M
- P/E
- —
- EPS
- -0.10
- Dividend yield
- —
- Beta (5Y)
- 1.07
- 52-week high
- $13.25
- 52-week low
- $5.65
- Avg volume (3M)
- —
- Shares outstanding
- 35.07M
- Employees
- 35
- Next earnings
- —
About Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
- ISIN
- CA31447P1009
- Founded
- 1996
- Listed since
- Sep 15, 2017
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $443.82 | +1.02% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.72 | +0.41% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.58 | -0.09% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.55 | +0.06% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $138.78 | -4.34% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.